Abstract:Macrocyclic molecules have emerged as significant contenders in drug development and supramolecular chemistry. Paritaprevir is a 15-membered macrocycle approved for the treatment of chronic Hepatitis C virus infection. The structural flexibility inherent in paritaprevir enables the presentation of diverse conformational features in solutions, thereby influencing its binding pattern with proteins. In this paper, we investigated the structural characteristics of paritaprevir in protic solvents (methanol and trifluoroethanol) as well as an aprotic solvent (acetonitrile) by using experimental electronic circular dichroism spectra combined with density functional theory calculations. Our study reveals that paritaprevir can adopt different molecular conformations due to its flexible carbon chain and the solvent environment. Conformer B is particularly stable in polar solvents because of the planar hydrophobic interactions between the phenanthridine and methylpyrazine groups. Density functional theory calculations-assisted structural analyses further disclosed the weak noncovalent interactions within the stable conformations of paritaprevir. Molecular docking of paritaprevir on different cancer proteins showed that the macrocycle was highly selective against lymphoma, endometrial carcinoma, colorectal cancer, and breast cancer. This suggests that paritaprevir could potentially serve as a promising lead compound for drug design targeting these specific types of cancers. The comparison between the low energy conformation and pharmacophore conformation (docking conformation) indicates that conformer B is the primary pharmacophore conformation of paritaprevir, providing important macrocyclic structural characteristics for future macrocyclic drug development.

Structure-activity Relationships of Cryptopleurine Analogs with E-ring Modifications As Anti-Hepatitis C Virus Agents.

Cryptopleurine Analogs With Modification Of E Ring Exhibit Different Mechanism To Rac-Cryptopleurine And Tylophorine

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Antitumor Agents 295. E-ring Hydroxylated Antofine and Cryptopleurine Analogues As Antiproliferative Agents: Design, Synthesis, and Mechanistic Studies.

Structure–activity relationship studies on quinoxalin-2(1 H )-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870

Synthesis and biological evaluation of ring A and/or C expansion and opening echinocystic acid derivatives for anti-HCV entry inhibitors

Elucidation of the Pharmacophore of Echinocystic Acid, a New Lead for Blocking HCV Entry.

Quinoxalin-2(1H)-One Derivatives As Inhibitors Against Hepatitis C Virus

Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Dimers as HCV Entry Inhibitors

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Lathyrane Diterpenoids As Novel Hpxr Agonists: Isolation, Structural Modification, and Structure-Activity Relationships

Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors

Identification of a Novel Class of Cyclic Penta-Peptides against Hepatitis C Virus as p7 Channel Blockers

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors

Elucidation of the Solution Structure of Macrocyclic Paritaprevir and Exploration of Its Antitumor Potential Through Molecular Docking

Studies of Benzothiadiazine Derivatives As Hepatitis C Virus NS5B Polymerase Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics.

Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis

Design, Synthesis, Anti-TMV Activity, and Structure-Activity Relationships of Seco-pregnane C21 Steroids and Their Derivatives

Bioisosteric replacement of the carboxylic acid group in Hepatitis-C virus NS5B thumb site II inhibitors: phenylalanine derivatives